July 23, 2015Open Access

Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials

Structured PICO

Does liposomal doxorubicin-based chemotherapy improve ORR and reduce cardiotoxicity in patients with advanced breast cancer?

Population

Patients with advanced breast cancer (meta-analysis of 10 randomized controlled trials)

Intervention

Liposomal doxorubicin-based chemotherapy

Outcome

Objective Response Rate (ORR) and cardiotoxicitysafety

Liposomal doxorubicin-based chemotherapy improves objective response rates and reduces cardiotoxicity in advanced breast cancer.

Abstract

The results of this meta-analysis suggest that liposomal doxorubicin-based chemotherapy is associated with a significant improvement in the ORR and a significant reduction in the risk of cardiotoxicity.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Xing et al. (Thu,) studied this question.

synapsesocial.com/papers/69d56e1c75589c71d767d3c8 https://doi.org/https://doi.org/10.1371/journal.pone.0133569

Perguntar à IA

Bookmark

View Full Paper